Abstract | BACKGROUND: OBJECTIVE: METHODS: This single-dose, double-blind, placebo-controlled study was conducted during the fall ragweed allergy season. Qualifying subjects attended one to two priming visits; those with sufficient symptom scores returned for treatment and were initially exposed to ragweed pollen for 90 minutes. Symptomatic subjects received fexofenadine- pseudoephedrine or placebo and recorded symptoms for 6 hours postdose. Efficacy variables were major symptom complex (MSC; sneezes, itchy nose, runny nose, watery eyes, itchy eyes, itchy ears/throat, stuffy nose), total symptom complex (nose blows, sniffles, postnasal drip, cough, plus all MSC symptoms), and all individual symptoms as well as headache. Onset of action for each efficacy variable was calculated as the earliest time at which a consistent, significant decrease was seen for fexofenadine- pseudoephedrine versus placebo. RESULTS: CONCLUSIONS:
|
Authors | Robert B Berkowitz, George G Woodworth, Cheryl Lutz, Kay Weiler, John Weiler, Madelyn Moss, Suzanne Meeves |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 89
Issue 1
Pg. 38-45
(Jul 2002)
ISSN: 1081-1206 [Print] United States |
PMID | 12141718
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Histamine H1 Antagonists
- Nasal Decongestants
- Terfenadine
- fexofenadine
- Ephedrine
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Double-Blind Method
- Drug Therapy, Combination
- Ephedrine
(administration & dosage, adverse effects)
- Female
- Histamine H1 Antagonists
(administration & dosage)
- Humans
- Male
- Middle Aged
- Nasal Decongestants
(administration & dosage)
- Rhinitis, Allergic, Seasonal
(drug therapy)
- Terfenadine
(administration & dosage, adverse effects, analogs & derivatives)
|